Sara Downs, DO
Internal Medicine · Pinellas Park, FLNPI 1548384480
Payments from drug & device makers
Across 367 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Boehringer Ingelheim$891
- AbbVie$811
- Novo Nordisk$584
- GSK$417
- Lilly USA, LLC$386
- plus $2K from 29 others
What the payments were for
- Food & beverage$7,176100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 101 | $1,921 |
| Boehringer Ingelheim | 42 | $891 |
| AbbVie(2 entities) | 37 | $811 |
| Novo Nordisk | 27 | $584 |
| GSK | 24 | $417 |
| Lilly USA, LLC | 23 | $386 |
| Johnson & Johnson | 22 | $385 |
| Sanofi-aventis U.S. LLC | 11 | $195 |
| Amarin Pharma, Inc. | 8 | $165 |
| Phathom Pharmaceuticals, Inc. | 2 | $164 |
| Abbott | 8 | $154 |
| Merck | 8 | $113 |
| Bayer | 4 | $108 |
| Amgen | 6 | $101 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $101 |
| Eisai Inc. | 4 | $90 |
| Amneal Pharmaceuticals LLC | 5 | $85 |
| Astellas Pharma US Inc | 3 | $65 |
| Kowa Pharmaceuticals America, Inc. | 4 | $63 |
| Insulet Corporation | 3 | $58 |
| Pfizer | 4 | $56 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Axsome Therapeutics, Inc. | 1 | $31 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $22 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Companion Medical, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Medline Industries LP | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Corcept Therapeutics | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,189 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 47 | $58,370 |
| XifaxanRifaximin | 11 | $40,971 |
| OzempicSemaglutide | 19 | $27,991 |
| JardianceEmpagliflozin | 15 | $24,198 |
| XareltoRivaroxaban | 12 | $20,002 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $12,526 |
| MyrbetriqMirabegron | 11 | $11,602 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $11,454 |
| FarxigaDapagliflozin Propanediol | 13 | $8,732 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,109 |
| LumiganBimatoprost | 12 | $3,139 |
| Levothyroxine Sodium | 250 | $2,617 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $2,459 |
| Losartan Potassium | 215 | $2,195 |
| Atorvastatin Calcium | 283 | $2,166 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $386 | $58,37047 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $101 | $40,97111 claims |
| Novo NordiskOzempic | $584 | $27,99119 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $1,921 | $24,29537 claims |
| Boehringer IngelheimJardiance | $891 | $24,19815 claims |
| Johnson & JohnsonXarelto | $385 | $20,00212 claims |
| Astellas Pharma US IncMyrbetriq | $65 | $11,60211 claims |
| AbbVieLumigan, Synthroid | $811 | $5,24736 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $85 | $2,617250 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Pinellas Park
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.